INTERNATIONAL PATENT: NANJING LEGEND BIOTECH CO., LTD., LEGEND BIOTECH IRELAND LIMITED FILES APPLICATION FOR "COMBINATION OF CLDN18.2 AND GUCY2C TARGETED ANTAGONIST THERAPY"

GENEVA, Jan. 27 -- NANJING LEGEND BIOTECH CO., LTD. (No.6 Building of Nanjing Life Science Town, No. 568 Longmian Avenue, Jiangning DistrictNanjing, Jiangsu 211100), LEGEND BIOTECH IRELAND LIMITED (10A Ballymoss Road, Sandyford Business ParkDublin 18, D18 T934) filed a patent application (PCT/CN2024/106351) for "COMBINATION OF CLDN18.2 AND GUCY2C TARGETED ANTAGONIST THERAPY" on Jul 19, 2024. With publication no. WO/2025/016450, the details related to the patent application was published on Jan 23, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): ZHUANG, Qiuchuan (No.6 Building of Nanjing Life...